In the following article the issue of Glycogen synthase kinase-3 beta will be addressed, which is a matter of utmost importance and relevance today. Glycogen synthase kinase-3 beta is a topic that has aroused the interest and attention of a large number of people around the world, and its impact extends to various areas of daily life. Along these lines, different aspects related to Glycogen synthase kinase-3 beta will be analyzed, providing detailed and updated information to deepen your understanding. In addition, various points of view and opinions of experts in the field will be explored, with the aim of offering a broad and enriching perspective on Glycogen synthase kinase-3 beta.
Glycogen synthase kinase-3 beta, (GSK-3 beta), is an enzyme that in humans is encoded by the GSK3B gene.[5][6] In mice, the enzyme is encoded by the Gsk3b gene.[7] Abnormal regulation and expression of GSK-3 beta is associated with an increased susceptibility towards bipolar disorder.[8]
Glycogen synthase kinase-3 (GSK-3) is a proline-directed serine-threonine kinase that was initially identified as a phosphorylating and an inactivating agent of glycogen synthase. Two isoforms, alpha (GSK3A) and beta, show a high degree of amino acid homology.[5] GSK3B is involved in energy metabolism, neuronal cell development, and body pattern formation.[9][10] It might be a new therapeutic target for ischemic stroke.
Homozygous disruption of the Gsk3b locus in mice results in embryonic lethality during mid-gestation.[7] This lethality phenotype could be rescued by inhibition of tumor necrosis factor.[7]
Two SNPs at this gene, rs334558 (-50T/C) and rs3755557 (-1727A/T), are associated with efficacy of lithium treatment in bipolar disorder.[11]
Pharmacological inhibition of ERK1/2 restores GSK-3 beta activity and protein synthesis levels in a model of tuberous sclerosis.[12]
GSK3B has been shown to interact with: